OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze

Overview

This episode dives into OpenAI's struggles to meet user and revenue targets, the competitive dynamics in AI cybersecurity, the explosive growth in hyperscaler CapEx driven by AI, the potential of new peptide drugs like Retatrutide, and a firsthand account of the Supreme Court's deliberations on federal regulatory authority.

Notable Quotes

- Sam may end up being right for the wrong reason—he missed on consumer, but enterprise is going gangbusters. - David Sacks, on OpenAI's pivot to enterprise success.

- Humans exploiting humans is where we've been for a long time. Now we have computers exploiting humans because the computers go and seek out all these bugs that humans wrote. - Chamath Palihapitiya, on the evolution of cybersecurity threats.

- Watching these Supreme Court lawyers argue is like watching LeBron James play basketball—it's awe-inspiring. - David Friedberg, on his experience attending a Supreme Court hearing.

🧠 OpenAI's Missed Targets and Strategic Shifts

- OpenAI failed to meet its 2025 user and revenue targets, with only 900 million weekly active users instead of the projected 1 billion.

- David Sacks highlighted that while consumer adoption lagged, enterprise use of ChatGPT 5.5 is thriving, particularly in coding applications.

- Anthropic's Opus 4.7 faced criticism for compute rationing, giving OpenAI a competitive edge with its new SPUD-based model.

- Chamath Palihapitiya emphasized that the AI market is constrained by power and compute availability, not demand, creating opportunities for hyperscalers like Amazon and Google.

🔒 AI Cybersecurity: A Booming Market

- OpenAI's GPT-5.5 Cyber model matches Anthropic's Mythos in automating cyber defense, marking a leap in AI-powered cybersecurity.

- David Sacks argued that these tools will empower white hat defenders to patch vulnerabilities before attackers exploit them.

- Concerns were raised about the potential misuse of these models, but Chamath Palihapitiya predicted a future where machines rewrite insecure human-coded software, escalating machine-vs-machine cyber battles.

💸 Hyperscaler CapEx Explosion

- Google, Microsoft, Amazon, and Meta collectively plan to spend $725 billion on CapEx in 2026, driven by AI and cloud computing demand.

- David Sacks noted this validates the AI bull thesis, with AI contributing 75% of recent GDP growth.

- Chamath Palihapitiya warned that hyperscalers are becoming asset-heavy, resembling industrial businesses, which could impact valuations.

- The panel compared this investment wave to the 2000s internet infrastructure boom, but Sacks dismissed fears of dark GPUs, citing insatiable demand for compute.

💊 Retatrutide and the Peptide Craze

- Retatrutide, a triple-agonist peptide drug, is generating excitement for its potential to reduce weight, improve metabolic health, and even slow aging.

- David Friedberg detailed its ability to favor fat burning over muscle loss, with trial participants losing an average of 37 pounds in 40 weeks.

- The drug also shows promise in reducing liver fat, cholesterol, and systemic inflammation, sparking interest beyond obesity treatment.

- Chamath Palihapitiya called it a wonder drug for its potential to address multiple health concerns, including cardiac and liver health.

⚖️ Supreme Court and Federal Preemption

- David Friedberg recounted attending a Supreme Court hearing on whether federal regulatory bodies like the EPA can preempt state laws in labeling products like Roundup.

- The case hinges on the Chevron doctrine, which limits deference to federal agencies, raising questions about state vs. federal authority.

- Friedberg described the courtroom as a sacred space, likening the lawyers' skill to elite athletes and emphasizing the institution's gravitas.

- The outcome could have far-reaching implications for regulatory consistency across industries.